Cargando…

Molecular Imaging in Parkinsonian Disorders—What’s New and Hot?

HIGHLIGHTS: Imaging of the dopamine transporter (DAT) (in particular using 11C- or 18F-PE2I) most reliably and precisely measures neurodegeneration of the dopaminergic system in parkinsonian disorders and its progression in longitudinal studies. Combining DAT imaging and iron- and neuromelanin-sensi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prange, Stéphane, Theis, Hendrik, Banwinkler, Magdalena, van Eimeren, Thilo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496752/ https://www.ncbi.nlm.nih.gov/pubmed/36138882 http://dx.doi.org/10.3390/brainsci12091146

Ejemplares similares

Imaging the Limbic System in Parkinson’s Disease—A Review of Limbic Pathology and Clinical Symptoms
por: Banwinkler, Magdalena, et al.
Publicado: (2022)

Unlucky punches: the vulnerability-stress model for the development of impulse control disorders in Parkinson’s disease
por: Theis, Hendrik, et al.
Publicado: (2021)

TSPO imaging in parkinsonian disorders
por: Gerhard, Alexander
Publicado: (2016)

Significance of clinical symptoms and red flags in early differential diagnosis of Parkinson’s disease and atypical Parkinsonian syndromes
por: Schröter, Nils, et al.
Publicado: (2023)

Impulsive-compulsive behaviour in early Parkinson’s disease is determined by apathy and dopamine receptor D3 polymorphism
por: Theis, Hendrik, et al.
Publicado: (2023)

Impulse control disorders in Parkinson’s disease: seeking a roadmap toward a better understanding
por: Cilia, Roberto, et al.
Publicado: (2011)

Utility of susceptibility-weighted imaging in Parkinson’s disease and atypical Parkinsonian disorders
por: Wang, Zhibin, et al.
Publicado: (2016)

Neuropsychiatric disturbances in atypical parkinsonian disorders
por: Belvisi, Daniele, et al.
Publicado: (2018)

Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System
por: van Eimeren, Thilo, et al.
Publicado: (2019)

Nephrotic syndrome: what's new, what's hot?
por: Kang, Hee Gyung, et al.
Publicado: (2015)

The Functional Anatomy of Impulse Control Disorders
por: Probst, Catharina C., et al.
Publicado: (2013)

Pseudobulbar Affect in Parkinsonian Disorders: A Review
por: Hakimi, Mathew, et al.
Publicado: (2019)

Autonomic Dysfunctions in Parkinsonian Disorders
por: Bae, Hyo-Jin, et al.
Publicado: (2009)

Assessing Bradykinesia in Parkinsonian Disorders
por: Pal, Gian, et al.
Publicado: (2013)

Assisted Suicide in Parkinsonian Disorders
por: Nuebling, Georg S., et al.
Publicado: (2021)

Dopamine transporter SPECT imaging in Parkinson’s disease and parkinsonian disorders
por: AKDEMİR, Ümit Özgür, et al.
Publicado: (2021)

Disorders of the Oral Cavity in Parkinson's Disease and Parkinsonian Syndromes
por: Zlotnik, Yair, et al.
Publicado: (2015)

Therapeutic Application of rTMS in Atypical Parkinsonian Disorders
por: Petsani, Chrysi, et al.
Publicado: (2021)

Biomarkers for parkinsonian disorders in CNS-originating EVs: promise and challenges
por: Dutta, Suman, et al.
Publicado: (2023)

Inhibitory framing in hypersexual patients with Parkinson’s disease. An fMRI pilot study
por: Theis, Hendrik, et al.
Publicado: (2022)

Central autonomic dysfunction in multiple system atrophy: can we measure it with MRI?
por: van Eimeren, Thilo
Publicado: (2020)

Imaging biomarkers in Parkinson’s disease and Parkinsonian syndromes: current and emerging concepts
por: Saeed, Usman, et al.
Publicado: (2017)

Cerebrospinal Fluid Biomarker Candidates for Parkinsonian Disorders
por: Constantinescu, Radu, et al.
Publicado: (2013)

Shared Metabolic Profile of Caffeine in Parkinsonian Disorders
por: Takeshige‐Amano, Haruka, et al.
Publicado: (2020)

Epidemiology of atypical parkinsonian syndromes
por: Lo, Raymond Y.
Publicado: (2021)

What Mechanisms Are Responsible for the Reuptake of Levodopa-Derived Dopamine in Parkinsonian Striatum?
por: Nishijima, Haruo, et al.
Publicado: (2016)

Biosignatures for Parkinson’s Disease and Atypical Parkinsonian Disorders Patients
por: Potashkin, Judith A., et al.
Publicado: (2012)

Sensor‐based gait analysis in atypical parkinsonian disorders
por: Raccagni, Cecilia, et al.
Publicado: (2018)

How Parkinsonian Toxins Dysregulate the Autophagy Machinery
por: Dagda, Ruben K., et al.
Publicado: (2013)

Computer-Aided Classification Framework of Parkinsonian Disorders Using (11)C-CFT PET Imaging
por: Xu, Jiahang, et al.
Publicado: (2022)

Neuropathological correlates of parkinsonian disorders in a large Dutch autopsy series
por: Geut, H., et al.
Publicado: (2020)

To respond or not to respond: exploring empathy-related psychological and structural brain differences between placebo analgesia responders and non-responders
por: Hartmann, Helena, et al.
Publicado: (2023)

A pill as a quick solution: association between painkiller intake, empathy, and prosocial behavior
por: Banwinkler, Magdalena, et al.
Publicado: (2023)

Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers
por: Pont-Sunyer, Claustre, et al.
Publicado: (2015)

Susceptibility-weighted MRI of extrapyramidal brain structures in Parkinsonian disorders
por: Schneider, Eva, et al.
Publicado: (2016)

Molecular Genetics of Keratinization Disorders – What’s New About Ichthyosis
por: UITTO, Jouni, et al.
Publicado: (2020)

PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes
por: Schönecker, Sonja, et al.
Publicado: (2019)

What Is Malaria? And Why Is It Most Intense in Hot Climates?
Publicado: (1871)

Assessment of Tau Tangles and Amyloid-β Plaques Among Super Agers Using PET Imaging
por: Hoenig, Merle C., et al.
Publicado: (2020)

Hot receptors in the brain
por: Steenland, Hendrik W, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_15unpnv5gba1d96a4dml2mqr1v